Pancreatic Cancer Vaccine Fails to Extend Survival

A phase 2 trial found the experimental camupepimut vaccine did not significantly improve disease-free survival in patients after surgery and chemotherapy.

Updated on Nov. 3, 2026 in Cancer

Bold flat-color editorial illustration of three amber glass vials with white stoppers on a slate surface, one vial catching light, evoking a clinical trial result. — A phase 2 trial of Gritstone Bio's experimental camupepimut pancreatic cancer vaccine failed to significantly improve disease-free survival in 144 patients after surgery and chemotherapy. AI Illustration. Upload story photo >

Live Poll

Should the government increase funding for experimental cancer research?

A phase 2 trial tested the experimental camupepimut vaccine in 144 patients with KRAS-mutated pancreatic cancer who had no detectable signs of cancer after surgery and chemotherapy. The vaccine did not significantly improve disease-free survival compared with observation.

Why it matters

The results show that a vaccine can trigger strong immune responses against tumor mutations without yet delivering a clear survival benefit. Researchers say the findings provide a basis for refining the approach before larger testing.

In a trial of 144 patients, 96 received the vaccine and 48 were observed, with average disease-free survival of 23.8 months versus 21.2 months, a gap that did not reach statistical significance. Nearly 99 percent of vaccinated patients developed increased T-cell responses against mutated KRAS, but whether a modified vaccine will yield a survival benefit remains unresolved.

The players

Mayo Clinic

A nonprofit academic medical center based in Rochester, Minnesota, whose researchers led the trial of the camupepimut vaccine.

The details

The vaccine delivers its ingredients to the lymph nodes by attaching to a fatty molecule that binds the blood protein albumin. Patients who had no detectable circulating tumor DNA at the start stayed cancer-free longer with the vaccine, a finding researchers say warrants further study.

Over 46 weeks after the study began, 95.5 percent of patients showed detectable T-cell responses to KRAS mutations.

Big Picture

The trial adds a data point to a field where personalized mRNA pancreatic cancer vaccine projects reported early findings in April. Its null survival result contrasts with the immune-response gains that such platforms have been shown to produce.

For patients with resected pancreatic cancer, the results indicate that this vaccine is not yet an established addition to post-surgery treatment. Patients considering experimental options should discuss trial eligibility and available standard therapies with their oncologists.

The takeaway

Immune-response data alone does not establish clinical benefit, and survival endpoints remain the decisive measure for cancer vaccines. Readers should weigh early trial signals carefully before assuming new therapies will change outcomes.